

1 **WO**

2  
3  
4  
5  
6  
7  
8 IN THE UNITED STATES DISTRICT COURT  
9 FOR THE DISTRICT OF ARIZONA

10 *IN RE: ZICAM COLD REMEDY*  
11 *MARKETING, SALES PRACTICES*  
12 *AND PRODUCTS LIABILITY*  
13 *LITIGATION*

No. 09-md-02096-PHX-FJM

**RULE 54(b) JUDGMENT, FINAL  
ORDER AND DECREE**

14 THIS DOCUMENT RELATES TO:  
15 All Economic Injury Actions.

16  
17 This matter comes before the Court on the Plaintiffs' Motion for Final Approval  
18 of Class Action Settlement and Application for Attorneys' Fees and Costs (doc. 1422).  
19 After review and consideration of the Settlement Agreement entered into by the Parties,  
20 and after hearing argument of the parties at the Final Approval Hearing held on May 27,  
21 2011 and there being no objections and no opt-outs,

22 **IT IS HEREBY ADJUDGED AND DECREED THAT:**

23 1. This Judgment incorporates by reference the definitions in the Amended  
24 Settlement Agreement dated February 23, 2011 ("Settlement Agreement") (doc. 1358),  
25 and all terms used in this order have the same meaning as set forth in the Settlement  
26 Agreement unless otherwise stated.

27 2. The Court has jurisdiction over the subject matter of this action and all  
28 Parties to the action, including all Settlement Class Members.

1           3. Pursuant to Rule 23(b)(3), Fed. R. Civ. P., the Court hereby certifies the  
2 following Settlement Class:

3           All persons in the United States who purchased Zicam Cold Remedy Nasal  
4 Spray, Zicam Cold Remedy Swabs, and/or Zicam Cold Remedy Swabs  
5 (kids size) for personal, family or household use between January 1, 1999  
6 and October 19, 2010 and claim that the products were not safe. Excluded  
7 from the class are all persons who suffered bodily injury arising from the  
8 use of these products.

9           4. Pursuant to Rule 23(a), Fed. R. Civ. P., the Court finds that the Class  
10 Representatives listed in Exhibit 2 to the Settlement Agreement are members of the Class,  
11 their claims are typical of the Class, and they fairly and adequately protected the interests  
12 of the Class throughout the proceedings in the Litigation. Accordingly, the Court hereby  
13 appoints those persons listed in Exhibit 2 to the Settlement Agreement as class  
14 representatives.

15           5. Further, the Court finds that the Settlement Class meets all the requirements  
16 of Rule 23(a) and (b)(3), Fed. R. Civ. P., for certification of the class claims alleged in the  
17 First Consolidated Amended Economic Injury Class Action Complaint, including: (a)  
18 numerosity; (b) commonality; (c) typicality; (d) adequacy of the class representatives and  
19 Class Counsel; (e) predominance of common questions of fact and law among the Class  
20 for purposes of settlement; and (f) superiority.

21           6. Having considered the factors set forth in Rule 23(g)(1), Fed. R. Civ. P., the  
22 Court finds that Class Counsel have fairly and adequately represented the Class for  
23 purposes of entering into and implementing the settlement, and thus, hereby appoints  
24 Class Counsel as counsel to represent the Settlement Class Members.

25           7. Pursuant to Rule 23(e)(2), Fed. R. Civ. P., the Court finds based upon all  
26 submissions of the Parties, the settlement proposed by the Parties is fair, reasonable, and  
27 adequate. The terms and provisions of the Settlement Agreement are the product of  
28 protracted, arms-length negotiations conducted in good faith and with the assistance of an  
experienced mediator, United States Magistrate Judge David K. Duncan, and numerous  
follow up conversations and negotiations between the parties. Approval of the Settlement

1 Agreement will result in substantial savings of time, money and effort to the Court and the  
2 Parties, and will further the interests of justice.

3 8. Neither the Settlement, this Judgment or the fact of the Settlement  
4 constitutes any admission by any of the Parties of any liability, wrongdoing or violation of  
5 law, damages or lack thereof, of the validity or invalidity of any claim or defense asserted  
6 in the Litigation.

7 9. The Court has considered the submissions by the Parties and all other  
8 relevant factors, including the result achieved and the efforts of Class Counsel in  
9 prosecuting the claims on behalf of the Class. Plaintiffs initiated the Litigation, acted to  
10 protect the Class, and assisted their counsel. The efforts of Class Counsel have produced  
11 the Settlement Agreement entered into in good faith, and which provides a fair,  
12 reasonable, adequate and certain result for the Class. Class Counsel is entitled to  
13 reasonable attorneys' fees and expenses for their work incurred in this Litigation, in the  
14 amount of \$150,000, an amount that Defendants agree to pay.

15 10. If any of the Zicam Cold Remedy Intra-Nasal Products are re-introduced to  
16 the market and sold by Defendants in the U.S., they will be labeled and bear any language  
17 regarding adverse effects as required by the U.S. Food and Drug Administration ("FDA").

18 11. Prior to re-introduction of any Zicam Cold Remedy Intra-Nasal Products to  
19 the market in the U.S., Defendant Matrixx Initiatives, Inc. will provide to Plaintiffs' Co-  
20 Lead Class Counsel 30 days advance notification, by certified mail, of the proposed  
21 labeling of such products, to enable Plaintiffs to ensure Defendants' compliance with the  
22 agreed-upon labeling language.

23 12. Plaintiffs requested, and Defendants did not oppose, and the Court thereby  
24 orders that all efficacy claims in the First Consolidated Amended Economic Injury Class  
25 Action Complaint be dismissed without prejudice pursuant to Rules 41(a)(2) and 23(e),  
26 Fed. R. Civ. P. Efficacy claims will be resolved in Hohman v. Matrixx Initiatives, Inc.,  
27 No. CV-09-3693, pending in the Northern District of Illinois. They will not be refiled  
28 here. The Court hereby dismisses with prejudice the remainder of Plaintiffs' safety claims

1 in each of the following economic injury actions, and each of the following actions in this  
2 MDL is dismissed:

3  
4 MDL First Consolidated Amended Economic Injury Class Action  
Complaint filed on March 22, 2010 in *In Re Zicam Marketing, Sales Practices  
5 and Products Liability Litigation* (MDL 2096)

6 *Jason Buszta v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for the  
District of Arizona, Case No. 2:09-cv-02310 (transferred from U.S. District  
7 Court for the Eastern District of Michigan, Case No. 2:09-cv -02310)

8 *Floyd Fessler v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for the  
District of Arizona, Case No. 2:09-cv-02139 (transferred from U.S. District  
9 Court for the Southern District of Illinois, Case No. 2:09-cv-02139)

10 *Kasey C. Hammett et al. v. Matrixx Initiatives, Inc., et al.*, U.S. District  
Court for the District of Arizona, Case No. 2:09-cv-02140 (transferred from  
11 U.S. District Court for the Southern District of Mississippi, Case No. 2:09-cv-  
02140)

12 *Vickie Hand et al. v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for  
the District of Arizona, Case No. 2:09-cv-02306 (transferred from U.S. District  
13 Court for the Northern District of Georgia, Case No. 2:09-cv-02306)

14 *Stefanie Riepe et al. v. Matrixx Initiatives, Inc., et al.* U.S. District Court for  
the District of Arizona, Case No. 2:09-cv-02141 (transferred from U.S. District  
15 Court for the Western District of Missouri, Case No. 2:09-cv-02141)

16 *Stewart Roper v. Matrixx Initiatives, Inc., et al.* U.S. District Court for the  
District of Arizona, Case No. 3:09-cv-08110

17  
18 *Barbara Sample v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for the  
District of Arizona, Case No. 2:09-cv-02135 (transferred from U.S. District  
19 Court for the Central District of California, Case No. 2:09-cv-04524)

20 *Stephen Willis Siferd v. Matrixx Initiatives, Inc., et al.*, U.S. District Court  
for the District of Arizona, Case No. 2:09-cv-02311 (transferred from U.S.  
21 District Court for the Eastern District of North Carolina, Case No. 2:09-cv-  
02311)

22 *Jay F. Sitzes, et al. v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for  
the District of Arizona, Case No. 2:09-cv-02303 (transferred from the U.S.  
23 District Court for the Northern District of Florida., Case No. 2:09-cv-02303)

24 *Joanne Suhr et al. v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for  
the District of Arizona, Case No. 2:09-cv-02562 (transferred from the U.S.  
25 District Court for the Northern District of Ohio, Case No. 2:09-cv-02562)

26 *Russell Surette v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for the  
District of Arizona, Case No. 2:10-cv-01686 (transferred from U.S. District  
27 Court of Massachusetts, Case No. 1:10-cv-11102).

28 *John Tassi v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for the

1 District of Arizona, Case No. 2:09-cv-02136 (transferred from the U.S. District  
2 Court for the Southern District of California, Case No. 3:09-cv-01450)

3 *Joshua Teperson v. Matrixx Initiatives, Inc., et al*, U.S. District Court for the  
4 District of Arizona, Case No. 2:09-cv-02137 (transferred from the U.S. District  
5 Court for the Southern District of California, Case No. 3:09-cv-01358)

6 *Mildred Thrasher et al. v. Matrixx Initiatives, Inc., et al.*, U.S. District Court  
7 for the District of Arizona, Case No. 2:09-cv- 02134 (transferred from the U.S.  
8 District Court for the Eastern District of Arkansas, Case No. 2:09-cv-02134)

9 *Brandon Webb, et al. v. Matrixx Initiatives, Inc., et al.*, U.S. District Court  
10 for the District of Arizona, Case No. 2:10-cv-00168 (transferred from U.S.  
11 District Court for the Northern District of Illinois, Case No. 1:09-cv-07225)

12 *Mary Young, et al. v. Matrixx Initiatives, Inc., et al.*, U.S. District Court for  
13 the District of Arizona, Case No. 2:09-02300 (transferred from the U.S. District  
14 Court for the Middle District of Alabama, Case No. 2:09-cv-02300)

15 13. In accordance with section 3.1 of the Settlement Agreement,

16 [T]he Settlement Class, each member of the Settlement Class, and Plaintiffs  
17 fully release and discharge Defendants set forth in Exhibit 1, any retail  
18 establishment that sold Zicam Cold Remedy Intra-Nasal Products, and all  
19 businesses or individuals employed or retained by Defendants to assist with any  
20 aspect of the manufacture, design, formulation, labeling, marketing, promotion,  
21 distribution or sale of any Zicam Cold Remedy Intra-Nasal Product, and their  
22 present and former parent companies, shareholders, officers, directors,  
23 employees, agents, servants, registered representatives, attorneys, insurers,  
24 affiliates and successors and assigns from any and all claims, actions,  
25 allegations, demands, rights, liabilities, and causes of action of every nature and  
26 description whatsoever, whether class, individual or otherwise in nature,  
27 damages, liabilities of any nature whatsoever, including costs, expenses,  
28 penalties, attorneys' fees under any federal or state law, and whether asserted  
directly or indirectly, or whether known or unknown that Plaintiffs or any  
member of the Zicam Cold Remedy Intra-Nasal Products Safety Settlement  
Class asserted or that could have been asserted (specifically excluding bodily  
injury and efficacy related claims as set forth below), based upon, arising out


1 of, or relating to, the safety of Zicam Cold Remedy Intra-Nasal Products,  
2 whether in law or equity, known or unknown, before any court or similar body.  
3 This release does not include claims for bodily injury or claims that Zicam Cold  
4 Remedy Intra-Nasal Products or Zicam Oral Products were not effective or that  
5 defendants lacked adequate scientific proof of their efficacy.

6 14. The Court finding that no reason exists for delay in ordering final judgment  
7 pursuant to Rule 54(b), Fed. R. Civ. P., the clerk is hereby directed to enter this final  
8 Judgment forthwith.

9 **IT IS ORDERED GRANTING** plaintiffs' Motion to Dismiss Efficacy Claims  
10 without prejudice (doc. 998).

11 **IT IS ORDERED GRANTING** plaintiffs' "Motion for Final Approval of the  
12 Zicam Cold Remedy Intra-nasal Products Safety Settlement Class for Injunctive Relief  
13 Only and Petition for Attorneys' Fees and Expenses" (doc. 1422).

14 Dated this 27<sup>th</sup> day of May, 2011.

15  
16   
17 

---

 Frederick J. Martone  
18 United States District Judge  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28